HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KOD
Kodiak Sciences Inc.
There isn't enough reported data to score KOD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KOD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
KOD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KOD PE Valuation
KOD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KOD Forward outlook
There aren't enough analyst estimates for KOD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over KOD on earnings, with more consistent year-over-year improvement.
KOD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.08 | +$0.03 |
| Q2 2026 | -$4.19 | -$0.40 |
| Q1 2026 | -$4.17 | -$0.55 |
| Q4 2025 | -$4.32 | -$0.97 |
| Q3 2025 | -$4.11 | -$0.45 |
| Q2 2025 | -$3.79 | -$0.02 |
| Q1 2025 | -$3.62 | +$0.82 |
| Q4 2024 | -$3.35 | +$1.62 |
KOD is still losing money, but less than at its worst: $4.08 per share over the past year, against $6.39 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KOD Quarterly Revenue
KOD and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KOD on cash generation, producing positive trailing cash flow while its opponent burns cash.
KOD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$45.8M | -$12.9M |
| Q2 2026 | -$46.6M | -$11.8M |
| Q1 2026 | -$41M | -$11.6M |
| Q4 2025 | -$39.4M | -$9.2M |
| Q3 2025 | -$32.9M | -$11.6M |
| Q2 2025 | -$34.8M | -$8.3M |
| Q1 2025 | -$29.3M | +$10.3M |
| Q4 2024 | -$30.2M | +$29.5M |
KOD has burned cash in almost every quarter: −$173M over the past year, against −$127M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KOD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KOD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +332K shares |
| 1 year | +19% | +10.1M shares |
| 3 years | +20% | +10.5M shares |
| 5 years | -76% | -196M shares |
| Available history | -67% | -126M shares |
KOD has 63M diluted shares, up 19% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KOD Net Leverage
KOD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KOD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.3 | Overbought |
| Stochastic | 94.1 | Overbought |
KOD's weekly RSI is 78 (overbought) and its Stochastic is 94 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KOD PE vs Healthcare Sector
KOD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KOD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.4 | 23% above |
| 20 week MA | $58.8 | 84% above |
| 50 week MA | $42.4 | 155% above |
| 100 week MA | $25.3 | 328% above |
| 200 week MA | $14.8 | 632% above |
KOD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
KOD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.7 | $30.8 | +110% |
| 2021 | $30.8 | $19.0 | -38% |
| 2022 | $19.0 | $7.03 | -63% |
| 2023 | $7.03 | $3.04 | -57% |
| 2024 | $3.04 | $9.98 | +228% |
| 2025 | $9.98 | $29.9 | +199% |
| 2026 YTD | $29.9 | $108.3 | +262% |
KOD has the edge over HIMS on returns for 2026, with the stronger performance.